ArticlePloS one2016
Targeting Tumor Cells with Anti-CD44 Antibody Triggers Macrophage-Mediated Immune Modulatory Effects in a Cancer Xenograft Model.
Article in PloS one, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 20 citations in OpenAlex.
- CD44: A New Prognostic Marker in Colorectal Cancer?Cancers · 2024Review
- CD44: A Multifunctional Mediator of Cancer Progression.Biomolecules · 2021Review
- An integrative microenvironment approach for laryngeal carcinoma: the role of immune/methylation/autophagy signatures on disease clinical prognosis and single-cell genotypes.Journal of Cancer · 2021Article
- Abnormal Glycosylation of Cancer Stem Cells and Targeting Strategies.Frontiers in oncology · 2021Review
- Gastrointestinal cancer stem cells as targets for innovative immunotherapy.World journal of gastroenterology · 2020Review
- Characterizing CD44 regulatory microRNAs as putative therapeutic agents in human melanoma.Oncotarget · 2019Article
- Dissecting the role of hyaluronan synthases in the tumor microenvironment.The FEBS journal · 2019Review
- The Interplay between Circulating Tumor Cells and the Immune System: From Immune Escape to Cancer Immunotherapy.Diagnostics (Basel, Switzerland) · 2018Review
- The Rho GTPase signalling pathway in urothelial carcinoma.Nature reviews. Urology · 2018Review
- Assessment of target-mediated uptake with immuno-PET: analysis of a phase I clinical trial with an anti-CD44 antibody.EJNMMI research · 2018Article
- Nanomedicines for dysfunctional macrophage-associated diseases.Journal of controlled release : official journal of the Controlled Release Society · 2017Review
- Cancer Cell Fusion: Mechanisms Slowly Unravel.International journal of molecular sciences · 2016Review
- CD44: A metastasis driver and therapeutic target.Oncoscience · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 3 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
CD44, a transmembrane receptor reported to be involved in various cellular functions, is overexpressed in several cancer types and supposed to be involved in the initiation, progression and prognosis of these cancers. Since the sequence of events following the blockage of the CD44-HA interaction has not yet been studied in detail, we profiled xenograft tumors by RNA Sequencing to elucidate the mode of action of the anti-CD44 antibody RG7356. Analysis of tumor and host gene-expression profiles led us to the hypothesis that treatment with RG7356 antibody leads to an activation of the immune system. Using cytokine measurements we further show that this activation involves the secretion of chemo-attractants necessary for the recruitment of immune cells (i.e. macrophages) to the tumor site. We finally provide evidence for antibody-dependent cellular phagocytosis (ADCP) of the malignant cells by macrophages.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.